We are live on ! Find out more
DP

Diadema Partners Portfolio holdings

AUM $791M
1-Year Est. Return 245.83%
This Fund
S&P 500
This Quarter Est. Return
+47.67%
1 Year Est. Return
+245.83%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$391M
AUM Growth
+$62.8M
Cap. Flow
-$30.5M
Cap. Flow %
-7.81%
Top 10 Hldgs %
31.01%
Holding
170
New
75
Increased
15
Reduced
22
Closed
40

Top Buys

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$13.9M
2
BMY icon
Bristol-Myers Squibb
BMY
+$6.07M
3
INDV icon
Indivior Pharmaceuticals
INDV
+$5.32M
4
ASND icon
Ascendis Pharma A/S
ASND
+$5.14M
5
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$4.07M

Top Sells

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$14.5M
2
LLY icon
Eli Lilly
LLY
+$11M
3
TGTX icon
TG Therapeutics
TGTX
+$10.2M
4
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$9.76M
5
SLNO
Soleno Therapeutics
SLNO
+$7.92M

Sector Composition

Rank Sector Weight
1 Miscellaneous 63.28%
2 Healthcare 36.72%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HRMY icon
76
Harmony Biosciences
HRMY
$2.49B
$1.38M 0.35%
+50,000
New +$1.72M
AMLX icon
77
Amylyx Pharmaceuticals
AMLX
$4.14B
$1.36M 0.35%
+100,000
New +$941K
RNAM
78
DELISTED
Avidity Biosciences
RNAM
$1.31M 0.33%
+30,000
New +$1.21M
DFTX
79
Definium Therapeutics
DFTX
$5.18B
$1.25M 0.32%
105,891
-52,645
-33% -$491K
AVXL icon
80
CALL
Anavex Life Sciences
AVXL
$222M
$1.24M 0.32%
+139,800
New +$1.42M
VTGN icon
81
VistaGen Therapeutics
VTGN
$11.2M
$1.24M 0.32%
349,789
-54,133
-13% -$162K
SKYE icon
82
CALL
Skye Bioscience
SKYE
$7.75M
$1.18M 0.3%
+37,500
New +$1.13M
CRMD icon
83
PUT
CorMedix
CRMD
$601M
$1.16M 0.3%
+100,000
New +$1.21M
MNKD icon
84
MannKind Corp
MNKD
$1.14B
$1.14M 0.29%
+212,475
New +$932K
SUPN icon
85
Supernus Pharmaceuticals
SUPN
$2.44B
$1.07M 0.27%
+22,348
New +$900K
EDIT icon
86
CALL
Editas Medicine
EDIT
$425M
$1.04M 0.27%
+300,000
New +$837K
FOLD
87
CALL
DELISTED
Amicus Therapeutics
FOLD
$1.04M 0.26%
131,400
– –
CPRX
88
DELISTED
Catalyst Pharmaceutical
CPRX
$985K 0.25%
+50,000
New +$1.03M
RVPH
89
DELISTED
REVIVA PHARMA HLDGS INC
RVPH
$924K 0.24%
125,346
-11,427
-8% -$97.1K
ARCT icon
90
Arcturus Therapeutics
ARCT
$460M
$900K 0.23%
+48,811
New +$784K
OLMA icon
91
CALL
Olema Pharmaceuticals
OLMA
$862M
$886K 0.23%
+90,500
New +$543K
TRVI icon
92
Trevi Therapeutics
TRVI
$2.11B
$785K 0.2%
85,830
-100,000
-54% -$750K
PBYI icon
93
CALL
Puma Biotechnology
PBYI
$496M
$722K 0.18%
+135,900
New +$576K
SLS icon
94
CALL
SELLAS Life Sciences
SLS
$2.3B
$644K 0.16%
400,000
– –
XERS icon
95
Xeris Biopharma Holdings
XERS
$1.49B
$608K 0.16%
+74,753
New +$497K
CTMX icon
96
CytomX Therapeutics
CTMX
$604M
$591K 0.15%
+185,286
New +$417K
MRNA icon
97
Moderna
MRNA
$61.5B
$517K 0.13%
+20,000
New +$558K
AYTU icon
98
AYTU BioPharma
AYTU
$21.8M
$513K 0.13%
+272,670
New +$630K
TNYA icon
99
Tenaya Therapeutics
TNYA
$156M
$511K 0.13%
+315,519
New +$318K
KOD icon
100
CALL
Kodiak Sciences
KOD
$2.01B
$455K 0.12%
+27,800
New +$240K
2 3
4
5 6

Similar funds

KAS
Kemnay Advisory Services New York $791M AUM 14.14% 1-Year Est. Return
FSAG
Financial Solutions Advisory Group Chicago, Illinois $791M AUM
KAS
KPP Advisory Services Louisville, Kentucky $791M AUM 28.5% 1-Year Est. Return
BSSFA
Baron Silver Stevens Financial Advisors Boca Raton, Florida $791M AUM 18.81% 1-Year Est. Return
GUB
Golden Unicorn BVI Road Town $792M AUM 60.81% 1-Year Est. Return
EA
Enclave Advisors Austin, Texas $790M AUM 21.99% 1-Year Est. Return
BBES
Buffalo Business & Estate Services Orchard Park, New York $793M AUM
GEA
Glen Eagle Advisors Kingston, New Jersey $793M AUM 21.06% 1-Year Est. Return

Diadema Partners's Q3 2025 Portfolio in Review

As of Q3 2025, Diadema Partners held 170 positions worth $391M, up 19% from $328M the previous quarter. Its ten largest holdings account for 31% of the portfolio.

Diadema Partners withdrew a net $30.5M in Q3 2025, closing 40 positions and reducing 22 holdings. Its most notable exit was Amgen, an estimated $14.5M position sold in full.

By sector, the portfolio is most concentrated in Miscellaneous at 63% of assets, up from 51% a quarter earlier, followed by Healthcare.

Against the trend, Diadema Partners opened a new position in Bristol-Myers Squibb worth $5.86M.

  • Diadema Partners's largest Q3 2025 buy was Bristol-Myers Squibb: 130,000 shares worth $5.86M.
  • Diadema Partners added most to Regeneron Pharmaceuticals in Q3 2025, an estimated $13.9M increase.
  • Diadema Partners's biggest Q3 2025 reduction was TG Therapeutics, cutting an estimated $10.2M.
  • Diadema Partners fully exited Amgen in Q3 2025, selling an estimated $14.5M.
  • Diadema Partners's ten largest holdings make up 31% of its $391M portfolio in Q3 2025.
  • Diadema Partners opened 75 new positions and closed 40 in Q3 2025.
  • Diadema Partners's portfolio value rose 19% quarter-over-quarter to $391M.

Based on Diadema Partners's 13F filing for Q3 2025, filed 14 Nov 2025.